Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined 25 cases of colorectal lymphoma with DLBCL-like morphology and classified them into germinal center B-cell like (GCB)/non-GCB subgroups by immunohistochemistry (IHC) for CD10, bcl-6 and MUM1, or into double-expressor (DE)/non-DE subgroups by IHC for bcl-2 and c-myc.
|
31734190 |
2020 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BCL2 expression determined by IHC is an independent pejorative prognostic biomarker in HIV-associated DLBCL in the recent era.
|
31468517 |
2020 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
'Double-hit' lymphoma (DHL) and 'double-expression' lymphoma (DEL) involving gene rearrangement and protein expression of MYC and BCL2/BCL6 have recently become the most commonly used terms to describe the poor prognostic types of diffuse large B-cell lymphoma (DLBCL).
|
31615842 |
2020 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/THs) include a group of diffuse large B-cell lymphomas (DLBCLs) with inferior outcomes after standard chemoimmunotherapy.
|
31527075 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas.
|
31039827 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For these reasons, we evaluated single-agent activity of venetoclax in the DLBCLs and identified a subset with limited sensitivity to BCL-2 blockade despite having genetic bases of BCL-2 dysregulation.
|
30322870 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The rearrangements of C-MYC, BCL2 and/or BCL6 which are common in diffuse large B-cell lymphoma (DLBCL) are typically absent in PLMBCL.
|
31728727 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemically detectable co-expression of MYC and BCL2 in the absence of translocations also portends an increased risk of relapse within the central nervous system, particularly in the setting of the activated B-cell-like subtype of diffuse large B-cell lymphoma.
|
30573511 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We retrospectively examined 127 cases of newly diagnosed diffuse large B-cell lymphoma (DLBCL), and used fluorescence in situ hybridization (FISH) to detect genetic abnormalities in <i>MYC, BCL2,</i> and <i>BCL6</i>.
|
30809101 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Clinical Significance of <i>BCL2</i>, C-<i>MYC</i>, and <i>BCL6</i> Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
|
31171907 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
|
30872780 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements have been categorized separately from diffuse large B-cell lymphoma or BL.
|
31229156 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-apoptotic Bcl-2 proteins are upregulated in different cancers, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL), enabling survival by inhibiting pro-apoptotic Bcl-2-family members and inositol 1,4,5-trisphosphate (IP<sub>3</sub>) receptor (IP<sub>3</sub>R)-mediated Ca<sup>2+</sup>-signaling.
|
29899382 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma.
|
30496802 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
|
31285189 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to understand the biologic underpinnings of HGBL-DH/TH with BCL2 rearrangements (HGBL-DH/TH- BCL2) and diffuse large B-cell lymphoma (DLBCL) morphology through examination of gene expression.
|
30523716 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The mass was diagnosed as DLBCL which was negative for CD20 and double expression of MYC and BCL-2.
|
30985716 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concurrent of MYC and BCL2 and/or BCL6 abnormalities and MYC/BCL2 double-expressor DLBCL occurred in all 3 patients; two patients had MYC/BCL2/BCL6 triple extra copies, and one patient had MYC extra copy and BCL6 translocation.
|
31109360 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical studies of the lymphoma tissues confirmed that overexpression of MYC and BCL2 was observed more frequently in this subtype than in other germinal center B-cell-like diffuse large B-cell lymphomas.
|
30523053 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Targeting MYC in the DHL/THL DLBCLs through bromodomain extra-terminal inhibitors (BETi) (JQ1, I-BET, and OTX015) significantly (p < 0.05) reduced proliferation, similar to WT-MYC cells, accompanied by decreased MYC but not BCL2 protein.
|
31288832 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Univariate analyses revealed that EZH2/Bcl-2 coexpression correlated to worse objective response rate (ORR), shorter OS and PFS in DLBCL patients treated with RCHOP while multivariate analysis indicated that only elevated LDH level (<i>P</i>=0.001) and presence of B symtom (<i>P</i>=0.008) rather than EZH2/Bcl-2 coexpression were associated with worse OS.
|
31205561 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma.
|
31601689 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Despite the recent therapeutic progress, the prognoses of diffuse large B-cell lymphomas (DLBCLs) that concomitantly overexpress c-MYC and BCL2, i.e., double hit lymphoma (DHL) and double expressing lymphoma (DEL), remain poor.
|
29931583 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding concurrent expression of MYC and BCL2 and/or BCL6 (double expressors (DE) and triple expressors (TE)), more DE and TE cases were found in the HGBL/DLBCL group than in the DLBCL group (25.53% vs 8.47%, p < 0.001, for DE cases and 55.32% vs 6.21%, p < 0.001, for TE cases).
|
31518494 |
2019 |
Diffuse Large B-Cell Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, either DLBCL or FL can give rise to aggressive double-hit lymphomas (DHL) with concurrent activation of MYC and BCL2.
|
30874346 |
2019 |